Get the Stockscreener App
0.752
4.58%
0.0329
Quoin Pharmaceuticals Ltd Adr stock is traded at $0.752, with a volume of 215.97K.
It is up +4.58% in the last 24 hours and up +55.40% over the past month.
Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.
See More
Previous Close:
$0.7191
Open:
$0.72
24h Volume:
215.97K
Relative Volume:
0.09
Market Cap:
$3.84M
Revenue:
-
Net Income/Loss:
$-8.28M
P/E Ratio:
-0.0164
EPS:
-45.9343
Net Cash Flow:
$-7.99M
1W Performance:
-14.57%
1M Performance:
+55.40%
6M Performance:
-3.13%
1Y Performance:
-83.10%
1-Day Range:
$0.7188
$0.77
1-Week Range:
$0.715
$0.89
52-Week Range:
$0.4772
$6.18
Quoin Pharmaceuticals Ltd Adr Stock (QNRX) Company Profile
Name
Quoin Pharmaceuticals Ltd Adr
Sector
Industry
Phone
97299741444
Address
23 HATA'AS STREET, KFAR SABA
Quoin Pharmaceuticals Ltd Adr Stock (QNRX) Latest News
Quoin Pharmaceuticals advances Netherton syndrome treatment trial - Investing.com
Quoin Pharmaceuticals granted extension to meet Nasdaq listing - Investing.com India
Quoin Pharmaceuticals expands UK clinical trials for rare disease - Investing.com
Quoin Pharmaceuticals sets date for 2024 shareholder meeting - Investing.com
Balance Sheet Insights: Quoin Pharmaceuticals Ltd ADR (QNRX)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - The Dwinnex
Quoin Pharmaceuticals CFO buys shares worth over $23,000 - Investing.com
Healthy Upside Potential: Quoin Pharmaceuticals Ltd ADR (QNRX) - SETE News
A closer look at QNRX’s price-to-free cash flow ratio - US Post News
Quoin Pharmaceuticals COO acquires $28,737 in company shares - Investing.com
Quoin Pharmaceuticals CEO acquires shares worth over $28k - Investing.com
Quoin Pharmaceuticals (NASDAQ:QNRX) Stock Quotes, Forecast and News Summary - Benzinga
QNRX Stock Hits 52-Week Low at $0.57 Amid Market Challenges - Investing.com Australia
Quoin Pharmaceuticals to Sponsor the Foundation for Ichthyosis & Related Skin Types (FIRST) 2024 National Conference - GlobeNewswire Inc.
Quoin Pharmaceuticals partners with UCC for drug delivery tech By Investing.com - Investing.com
Quoin Pharmaceuticals director Dennis Langer sells shares worth $217 - Investing.com India
Quoin Pharmaceuticals director Dennis Langer sells shares worth $217 By Investing.com - Investing.com
Quoin Pharmaceuticals Provides Corporate Update and Announces First Quarter 2024 Financial Results - Investing.com South Africa
symbol__ Stock Quote Price and Forecast - CNN
GLMD Stock Quote Price and Forecast - CNN
U.S. shares lower at close of trade; Dow Jones Industrial Average down 1.04% - Investing.com India
Major Indexes Muted Following Strong Jobs Report - Schaeffers Research
Quoin Pharmaceuticals (QNRX) Stock Price, News & Analysis - MarketBeat
ADVFNFree stock and cryptocurrency prices, charts, market news and streaming real-time quotes. - ADVFN
Quoin Pharmaceuticals Ltd Adr Stock (QNRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Quoin Pharmaceuticals Ltd Adr Stock (QNRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Dunn Gordon | Chief Financial Officer |
Sep 09 '24 |
Buy |
0.79 |
8,856 |
7,005 |
8,856 |
| Carter Denise P. | Chief Operating Officer |
Sep 04 '24 |
Buy |
0.78 |
31,813 |
24,912 |
47,092 |
| Carter Denise P. | Chief Operating Officer |
Sep 03 '24 |
Buy |
0.65 |
5,922 |
3,825 |
15,279 |
| Myers Michael | Chief Executive Officer |
Sep 04 '24 |
Buy |
0.77 |
37,094 |
28,421 |
47,252 |
| Myers Michael | Chief Executive Officer |
Sep 03 '24 |
Buy |
0.62 |
800 |
495 |
10,158 |
| LANGER DENNIS | Director |
Jun 07 '24 |
Sale |
0.73 |
297 |
217 |
53 |
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):